Technology
Health
Biotechnology

Audentes Therapeutics

$36.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.79 (5.22%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell BOLD and other stocks, options, ETFs, and crypto commission-free!

About BOLD

Audentes Therapeutics, Inc. Common Stock, also called Audentes Therapeutics, is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Read More Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.

Employees
207
Headquarters
San Francisco, California
Founded
2012
Market Cap
1.50B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
521.98K
High Today
$36.19
Low Today
$34.15
Open Price
$34.40
Volume
333.43K
52 Week High
$42.70
52 Week Low
$17.95

Collections

Technology
Health
Biotechnology
Therapy
2016 IPO
US
North America

BOLD Earnings

-$1.13
-$1.00
-$0.87
-$0.74
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.